Tag archive for ‘Gene therapy company’
By pharmanewsdaily On Saturday, January 23rd, 2021
0 Comments

Lilly wraps up acquisition of gene therapy company Prevail Therapeutics

Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US pharma giant said that the deal gives it a new modality More...

By pharmanewsdaily On Wednesday, December 16th, 2020
0 Comments

Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal

Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative More...

By pharmanewsdaily On Thursday, December 3rd, 2020
0 Comments

HMR59 : Janssen acquires rights to geographic atrophy treatment candidate from Hemera

Geographic atrophy treatment : Janssen Pharmaceuticals has signed a licensing deal to acquire rights to HMR59, an investigational gene therapy for geographic atrophy, from clinical stage ocular gene therapy company More...

MSCP wraps up $330m sale of majority stake in Hojeij Branded Foods to Lagardere
By pharmanewsdaily On Wednesday, June 17th, 2020
0 Comments

Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round

California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 million through a Series More...

By pharmanewsdaily On Tuesday, December 24th, 2019
0 Comments

Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene More...

By pharmanewsdaily On Sunday, December 8th, 2019
0 Comments

Astellas Pharma to acquire US gene therapy company Audentes Therapeutics

Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition More...

By pharmanewsdaily On Tuesday, November 26th, 2019
0 Comments

Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in nadofaragene firadenovec (rAd-IFN/Syn3), More...

By pharmanewsdaily On Wednesday, October 30th, 2019
0 Comments

Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma

Cellectis said that it has dosed the first patient in a phase 1  study – the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf CAR-T product candidate for the treatment of relapsed/refractory More...

By pharmanewsdaily On Friday, October 25th, 2019
0 Comments

Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease

US gene therapy company Avrobio has secured orphan-drug designation for AVR-RD-02, its investigational gene therapy, for the treatment of Gaucher disease, from the US Food and Drug Administration (FDA). AVR-RD-02 More...

By pharmanewsdaily On Thursday, September 6th, 2018
0 Comments

Gene therapy company 4D Molecular Therapeutics raises $90m in new funding

California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $90 million through a Series More...